Cardiotoxicity of Carbon Monoxide in Patients Treated With Hyperbaric Oxygen Therapy

Recruiting

• Conditions: Carbon Monoxide Poisoning

• Registration Number: NCT06549621
• Lead Sponsor: University Hospital, Brest

Brief Summary

Carbon monoxide poisoning is a frequent domestic accident and the leading cause of death from unintentionnal poisoning. Its toxicity is based on the CO binding to hemoglobin and myoglobin, inhibition of mitochondrial cytochrome oxidase, resulting in tissue hypoxia and reduced adenosine triphosphate synthesis and ischemia-reperfusion injury.

This study aims to investigate the early and late cardiologic effects of CO in patients treated with hyperbaric oxygen (HBOT) for CO poisoning

Detailed Description

This is a single-center retrospective study on health data. The methodology includes a collection of data on health and history data of patients treated by HBOT fo CO poisoning between 01/01/2015 and 31/12/2021 and carrying out a telephone interview of patients who have had early cardiovascular manifestations of CO poisoning.

One month between the start of theses interviews, an information letter on the study is sent by post, giving the possibility of opposing it.

Study Timeline

• Study Start: 2022-07-25
• Primary Completion: 2022-10-25
• Status Verified: 2024-08
• Study First Submitted: 2024-08-08
• Study First Submitted QC: 2024-08-08
• Last Update Submitted: 2024-08-08
• Study First Posted: 2024-08-12
• Last Update Posted: 2024-08-12
• Study Completion: 2024-10-25

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 66

Inclusion Criteria

Patients treated for CO poisoning with HBOT in the hyperbaric and underwater medicine department of the Brest University hospital from 2015/01/01 to 2021/12/31

Exclusion Criteria

• refusal

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
early and late cardiac injury due to CO poisoning description	enrollment (inclusion)	clinical manifestation, troponin elevation and/or ECG abnormality during acute CO poisoning description; then late cardiac manifestation and abnormality declared by patients who have had early cardiac abnormality (troponin elevation and/or ECG abnormalities)

Secondary Outcome Measures

Name	Time	Method
relationship between cardiovascular risk factors or preexisting cardio vascular abnormality and cardiac injury	enrollment (inclusion)	comparison between the group of patients with early cardiac abnormalities (troponin elevation and/or ECG abnormalities) and the group of patients without early cardiac abnormalities using Ficher test
relationship between other possibly associated poisoning and cardiac injury	enrollment (inclusion)	comparison between the group of patients with early cardiac abnormalities (troponin elevation and/or ECG abnormalities) and the group of patients without early cardiac abnormalities using Ficher test
relationship between severity of neurological symptoms and cardiac injury	enrollment (inclusion)	comparison between the group of patients with early cardiac abnormalities (troponin elevation and/or ECG abnormalities) and the group of patients without early cardiac abnormalities using Ficher test
relationship between the source of CO poisoning and cardiac injury	enrollment (inclusion)	comparison between the group of patients with early cardiac abnormalities (troponin elevation and/or ECG abnormalities) and the group of patients without early cardiac abnormalities using Ficher test
relationship between context of poisoning (domestic, professionnal or intentional poisoning) and cardiac injury	enrollment (inclusion)	comparison between the group of patients with early cardiac abnormalities (troponin elevation and/or ECG abnormalities) and the group of patients without early cardiac abnormalities using Ficher test

Trial Locations

Locations (1)

CHRU de Brest; 🇫🇷 Brest, France